Skip to main content
Clinical Trials/NCT06184815
NCT06184815
Not yet recruiting
Not Applicable

Effectiveness of a Multidisciplinary Treatment and Structured Education for Type 1 Diabetes Patients

Instituto Mexicano del Seguro Social0 sites120 target enrollmentJanuary 1, 2024
ConditionsType 1 Diabetes

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 1 Diabetes
Sponsor
Instituto Mexicano del Seguro Social
Enrollment
120
Primary Endpoint
Changes in Glycemic Control Measured by A1c
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

This trial compared an structured education programme and multidisciplinary treatment vs an standard treatment in type 1 diabetes patient, the Primary outcome is glycemic control at 6-month follow up and secondary outcome are cardiovascular risk factors control, diabetes related distress, anxiety and depressive symptoms, hypoglycemia awareness.

Detailed Description

Both groups will received individualized treatment in the clinic, the intervention group will consist of 12 educational sessions during 4 months, and multidisciplinary treatment each month given by endocrinology, nutrition and psychology during 4 months, the control group will received education in outpatient clinic of endocrinology and will be sent as referral to specialties of nutrition and psychology as standard follow-up of the clinic.

Registry
clinicaltrials.gov
Start Date
January 1, 2024
End Date
November 30, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

David Sanchez Garcia

Principal investigator

Instituto Mexicano del Seguro Social

Eligibility Criteria

Inclusion Criteria

  • Type 1 diabetes
  • Diabetes duration \>1 year
  • BMI 18.5-40kg/m2
  • A1c 6.5-13%

Exclusion Criteria

  • Pregnancy
  • Dementia or severe cognitive impairment
  • Uncontrolled psychiatric disorder
  • Absence of \>20% of the educational sessions

Outcomes

Primary Outcomes

Changes in Glycemic Control Measured by A1c

Time Frame: Baseline and 6 months

Difference between baseline A1c and A1c at 6 month follow up

Secondary Outcomes

  • Changes in Lipid Control Measured by LDLc, HDLc, non-HDLc, Triglycerides, Total Cholesterol(Baseline and 6 months)
  • Changes in insulin resistance control Measured by eGDR(Baseline and 6 months)
  • Changes Anthropometry Measured by BMI and WC(Baseline and 6 months)
  • Changes in Glycemic Control Measured by severe hypoglycemia(Baseline and 6 months)
  • Changes in Mental health Measured by DDS, GAD7 and PHQ9(Baseline and 6 months)

Similar Trials